{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:31Z","timestamp":1793291611526,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41391-026-01137-0","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:42:58Z","timestamp":1787586178000},"page":"999-1004","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correlation of intraprostatic lesional SUVmax during PSMA PET\/CT and adverse pathology at radical prostatectomy"],"prefix":"10.1038","volume":"29","author":[{"given":"Felix","family":"Preisser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Nohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5660-7691","authenticated-orcid":false,"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-1380","authenticated-orcid":false,"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"1137_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"1137_CR2","unstructured":"Cornford P, Tilki D, Van Den Bergh RCN, Eberli D, De Meerleer G, De Santis M, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. 2026. https:\/\/uroweb.org\/guidelines\/prostate-cancer\/related-content."},{"key":"1137_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","volume":"195","author":"T Maurer","year":"2016","unstructured":"Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195:1436\u201343. https:\/\/doi.org\/10.1016\/j.juro.2015.12.025.","journal-title":"J Urol"},{"key":"1137_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00345-018-2182-1","volume":"36","author":"J Corfield","year":"2018","unstructured":"Corfield J, Perera M, Bolton D, Lawrentschuk N. 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol. 2018;36:519\u201327. https:\/\/doi.org\/10.1007\/s00345-018-2182-1.","journal-title":"World J Urol"},{"key":"1137_CR5","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.2967\/jnumed.117.190314","volume":"58","author":"SA Koerber","year":"2017","unstructured":"Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, et al. 68Ga-PSMA-11 PET\/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. J Nucl Med. 2017;58:1943\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.190314.","journal-title":"J Nucl Med"},{"key":"1137_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/bju.14794","volume":"124","author":"MJ Scheltema","year":"2019","unstructured":"Scheltema MJ, Chang JI, Stricker PD, van Leeuwen PJ, Nguyen QA, Ho B, et al. Diagnostic accuracy of 68Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68Ga-PSMA PET to mpMRI. BJU Int. 2019;124:42\u20139. https:\/\/doi.org\/10.1111\/bju.14794.","journal-title":"BJU Int"},{"key":"1137_CR7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.21873\/invivo.13211","volume":"37","author":"P Pepe","year":"2023","unstructured":"Pepe P, Pepe L, Tamburo M, Marletta G, Savoca F, Pennisi M, et al. 68Ga-PSMA PET\/CT and Prostate Cancer Diagnosis: Which SUVmax Value?. Vivo. 2023;37:1318\u201322. https:\/\/doi.org\/10.21873\/invivo.13211.","journal-title":"Vivo"},{"key":"1137_CR8","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1002\/cam4.5516","volume":"12","author":"N Yi","year":"2023","unstructured":"Yi N, Wang Y, Zang S, Yang L, Liu H, Sun H, et al. Ability of 68Ga-PSMA PET\/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate-risk prostate cancer: A single-center retrospective study of 147 patients. Cancer Med. 2023;12:7140\u20138. https:\/\/doi.org\/10.1002\/cam4.5516.","journal-title":"Cancer Med"},{"key":"1137_CR9","doi-asserted-by":"publisher","first-page":"8396","DOI":"10.7150\/thno.58140","volume":"11","author":"J Jiao","year":"2021","unstructured":"Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, et al. Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET\/CT: a real-world study. Theranostics. 2021;11:8396\u2013411. https:\/\/doi.org\/10.7150\/thno.58140.","journal-title":"Theranostics"},{"key":"1137_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bju.16482","volume":"134","author":"MJ Roberts","year":"2024","unstructured":"Roberts MJ, Papa N, Veerman H, de Bie K, Morton A, Franklin A, et al. Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics. BJU Int. 2024;134:47\u201355. https:\/\/doi.org\/10.1111\/bju.16482.","journal-title":"BJU Int"},{"key":"1137_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/JU.0000000000002293","volume":"207","author":"S Raveenthiran","year":"2022","unstructured":"Raveenthiran S, Yaxley WJ, Franklin T, Coughlin G, Roberts M, Gianduzzo T, et al. Findings in 1,123 Men with Preoperative 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography\/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Implications for the Diagnosis and Management of Prostate Cancer. J Urol. 2022;207:573\u201380. https:\/\/doi.org\/10.1097\/JU.0000000000002293.","journal-title":"J Urol"},{"key":"1137_CR12","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1007\/s00259-022-05756-2","volume":"49","author":"MJ Roberts","year":"2022","unstructured":"Roberts MJ, Morton A, Papa N, Franklin A, Raveenthiran S, Yaxley WJ, et al. Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2022;49:3289\u201394. https:\/\/doi.org\/10.1007\/s00259-022-05756-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1137_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","volume":"20","author":"MJ Roberts","year":"2023","unstructured":"Roberts MJ, Maurer T, Perera M, Eiber M, Hope TA, Ost P, et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat Rev Urol. 2023;20:23\u201347. https:\/\/doi.org\/10.1038\/s41585-022-00670-6.","journal-title":"Nat Rev Urol"},{"key":"1137_CR14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/bju.16608","volume":"135","author":"DC Chen","year":"2025","unstructured":"Chen DC, Huang S, Papa N, Siva S, Bolton DM, Lawrentschuk N, et al. Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis. BJU Int. 2025;135:720\u201332. https:\/\/doi.org\/10.1111\/bju.16608.","journal-title":"BJU Int"},{"key":"1137_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2009.05.044","volume":"56","author":"L Bud\u00e4us","year":"2009","unstructured":"Bud\u00e4us L, Isbarn H, Schlomm T, Heinzer H, Haese A, Steuber T, et al. Current Technique of Open Intrafascial Nerve-Sparing Retropubic Prostatectomy. Eur Urol. 2009;56:317\u201324. https:\/\/doi.org\/10.1016\/j.eururo.2009.05.044.","journal-title":"Eur Urol"},{"key":"1137_CR16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2015.07.037","volume":"69","author":"U Michl","year":"2016","unstructured":"Michl U, Tennstedt P, Feldmeier L, Mandel P, Oh SJ, Ahyai S, et al. Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy. Eur Urol. 2016;69:584\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.037.","journal-title":"Eur Urol"},{"key":"1137_CR17","unstructured":"R: The R Project for Statistical Computing. 2024. https:\/\/www.r-project.org\/."},{"key":"1137_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, Shamni O, Gitstein G, Hershkovitz D, et al. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med. 2020;61:527\u201332. https:\/\/doi.org\/10.2967\/jnumed.119.234187.","journal-title":"J Nucl Med"},{"key":"1137_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MNM.0000000000000942","volume":"40","author":"E Demirci","year":"2019","unstructured":"Demirci E, Kabasakal L, \u015eahin OE, Akg\u00fcn E, G\u00fcltekin MH, Do\u011fanca T, et al. Can SUVmax values of Ga-68-PSMA PET\/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019;40:86\u201391. https:\/\/doi.org\/10.1097\/MNM.0000000000000942.","journal-title":"Nucl Med Commun"},{"key":"1137_CR20","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.3390\/diagnostics13142343","volume":"13","author":"KCC De Bie","year":"2023","unstructured":"De Bie KCC, Veerman H, Bodar YJL, Meijer D, Van Leeuwen PJ, Van Der Poel HG, et al. Higher Preoperative Maximum Standardised Uptake Values (SUVmax) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [68Ga]Ga-PSMA-11 and [18F]DCFPyL Positron Emission Tomography\/Computed Tomography. Diagnostics. 2023;13:2343. https:\/\/doi.org\/10.3390\/diagnostics13142343.","journal-title":"Diagnostics"},{"key":"1137_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.745530","volume":"11","author":"X Qiu","year":"2021","unstructured":"Qiu X, Chen M, Yin H, Zhang Q, Li H, Guo S, et al. Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative 68Ga-PSMA-11 PET\/CT. Front Oncol. 2021;11:745530. https:\/\/doi.org\/10.3389\/fonc.2021.745530.","journal-title":"Front Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01137-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01137-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01137-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:02:16Z","timestamp":1793289736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01137-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1137"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01137-0","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"a) All methods were performed in accordance with the relevant guidelines and regulations. b) Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the University Hospital Hamburg Eppendorf. Because this is a retrospective study, there is no approval number for each study. c) Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}